Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...

Tagrisso (osimertinib)​ for adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) ...

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a ...

AstraZeneca announced on Thursday that ‘Tagrisso’, or osimertinib, has been approved by the US Food and Drug Administration ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...

The US Food and Drug Administration (FDA) has approved a new indication for AstraZeneca’s Tagrisso (osimertinib), which is ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC).